On October 13, the drug manufacturer Sanofi made a surprising announcement: Public demand for Beyfortus - the brand name of nirsevimab, the company’s new product aimed at protecting newborns from severe respiratory syncytial virus (RSV) infections - had wildly outpaced supply.